The hexane extract of Saussurea lappa and its active principle, dehydrocostus lactone, inhibit prostate cancer cell migration

Journal of Medicinal Food

Volumn 15, Issue 1, 2012, Pages 24-32

  Kim, Eun Ji ^a   Hong, Ji Eun ^a   Lim, Soon Sung ^a   Kwon, Gyoo Taik ^a   Kim, Jongdai ^b   Kim, Jong Sang ^c   Lee, Ki Won ^d,e   Park, Jung Han Yoon ^a,b  

^a Hallym University   (South Korea)

^b Kangwon National University   (South Korea)

^c Kyungpook National University   (South Korea)

^d Seoul National University   (South Korea)

^e Seoul National University   (South Korea)

Author keywords

dehydrocostus lactone; matrix metalloproteinase; migration; prostate cancer cells; Saussurea lappa

Indexed keywords

DEHYDROCOSTUS LACTONE; EPIDERMAL GROWTH FACTOR; GELATINASE B; SAUSSUREA LAPPA EXTRACT; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ARTICLE; CANCER CELL; CANCER CELL CULTURE; CARBON NUCLEAR MAGNETIC RESONANCE; CELL MIGRATION; CELL VIABILITY; COLUMN CHROMATOGRAPHY; CONTROLLED STUDY; ENZYME RELEASE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE CANCER; PROTON NUCLEAR MAGNETIC RESONANCE; SAUSSUREA; STIMULATION;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL LINE, TUMOR; CELL MOVEMENT; CELL SURVIVAL; CHROMATOGRAPHY; DOSE-RESPONSE RELATIONSHIP, DRUG; EPIDERMAL GROWTH FACTOR; HUMANS; LACTONES; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MATRIX METALLOPROTEINASE 9; MICE; PHYTOTHERAPY; PLANT EXTRACTS; PROSTATIC NEOPLASMS; SAUSSUREA; SESQUITERPENES; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TISSUE INHIBITOR OF METALLOPROTEINASE-2;

SAUSSUREA LAPPA;

EID: 84862786824     PISSN: 1096620X     EISSN: 15577600     Source Type: Journal    
DOI: 10.1089/jmf.2011.1735     Document Type: Article

References (42)

1. Jemal A, Siegel R, Xu J, Ward E: Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300. Erratum in CA Cancer J Clin 2011;61:133-134.
2. Abate-Shen C, Shen MM: Molecular genetics of prostate cancer. Genes Dev 2000;14:2410-2434.
3. Kasamon KM, Dawson NA: Update on hormone-refractory prostate cancer. Curr Opin Urol 2004;14:185-193. (Pubitemid 38582318)
4. Bonaccorsi L, Carloni V, Muratori M, Salvadori A, Giannini A, Carini M, Serio M, Forti G, Baldi E: Androgen receptor expression in prostate carcinoma cells suppresses alpha6beta4 integrin-mediated invasive phenotype. Endocrinology 2000;141: 3172-3182. (Pubitemid 32269005)
5. Cinar B, Koeneman KS, Edlund M, Prins GS, Zhau HE, Chung LW: Androgen receptor mediates the reduced tumor growth, enhanced androgen responsiveness, and selected target gene transactivation in a human prostate cancer cell line. Cancer Res 2001;61:7310-7317. (Pubitemid 32946530)
6. Bubendorf L, Schopfer A, Wagner U, Sauter G, Moch H, Willi N, Gasser TC, Mihatsch MJ: Metastatic patterns of prostate cancer: An autopsy study of 1,589 patients. Hum Pathol 2000;31: 578-583. (Pubitemid 30323983)
7. Chambers AF, MacDonald IC, Schmidt EE, Morris VL, Groom AC: Clinical targets for anti-metastasis therapy. Adv Cancer Res 2000;79:91-121.
8. Mehlen P, Puisieux A. Metastasis: A question of life or death. Nat Rev 2006;6:449-458.
9. Stetler-Stevenson WG, Aznavoorian S, Liotta LA: Tumor cell interactions with the extracellular matrix during invasion and metastasis. Annu Rev Cell Biol 1993;9:541-573.
10. Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM: Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol 2000;18:1135-1149. (Pubitemid 30123793)
11. Still K, Robson CN, Autzen P, Robinson MC, Hamdy FC: Localization and quantification of mRNA for matrix metalloproteinase- 2 (MMP-2) and tissue inhibitor of matrix metalloproteinase- 2 (TIMP-2) in human benign and malignant prostatic tissue. Prostate 2000;42:18-25. (Pubitemid 30004871)
12. Ross JS, Kaur P, Sheehan CE, Fisher HA, Kaufman RA Jr, Kallakury BV: Prognostic significance of matrix metalloproteinase 2 and tissue inhibitor of metalloproteinase 2 expression in prostate cancer. Mod Pathol 2003;16:198-205. (Pubitemid 36337424)
13. Brew K, Dinakarpandian D, Nagase H. Tissue inhibitors of metalloproteinases: Evolution, structure and function. Biochim Biophys Acta 2000;1477:267-283. (Pubitemid 30119906)
14. Hidalgo M, Eckhardt SG: Matrix metalloproteinase inhibitors: how can we optimize their development? Ann Oncol 2001;12: 285-287. (Pubitemid 32288682)
15. Duke JA, Ayensu ES: Medicinal Plants of China, Vol. 1. References Publications Inc., Algonac, MI, 1985.
16. Yoshikawa M, Hatakeyama S, Inoue Y, Yamahara J. Saussureamines A, B, C, D, and E, new anti-ulcer principles from Chinese Saussureae Radix. Chem Pharm Bull 1993;41:214-216. (Pubitemid 23071649)
17. Cho JY, Baik KU, Jung JH, Park MH: In vitro anti-inflammatory effects of cynaropicrin, a sesquiterpene lactone, from Saussurea lappa. Eur J Pharmacol 2000;398:399-407. (Pubitemid 30349105)
18. Ko SG, Koh SH, Jun CY, Nam CG, Bae HS, Shin MK: Induction of apoptosis by Saussurea lappa and Pharbitis nil on AGS gastric cancer cells. Biol Pharm Bull 2004;27:1604-1610.
19. Ko SG, Kim HP, Jin DH, Bae HS, Kim SH, Park CH, Lee JW: Saussurea lappa induces G2-growth arrest and apoptosis in AGS gastric cancer cells. Cancer Lett 2005;220:11-19. (Pubitemid 40312013)
20. Oh GS, Pae HO, Chung HT, Kwon JW, Lee JH, Kwon TO, Kwon SY, Chon BH, Yun YG: Dehydrocostus lactone enhances tumor necrosis factor-alpha-induced apoptosis of human leukemia HL-60 cells. Immunopharmacol Immunotoxicol 2004;26: 163-175. (Pubitemid 38738039)
21. Sun CM, Syu WJ, Don MJ, Lu JJ, Lee GH: Cytotoxic sesquiterpene lactones from the root of Saussurea lappa. J Nat Prod 2003;66:1175-1180.
22. Kim EJ, Lim SS, Park SY, Shin HK, Kim JS, Park JH: Apoptosis of DU145 human prostate cancer cells induced by dehydrocostus lactone isolated from the root of Saussurea lappa. Food Chem Toxicol 2008;46:3651-3658.
23. Hsu YL, Wu LY, Kuo PL: Dehydrocostuslactone, a medicinal plant-derived sesquiterpene lactone, induces apoptosis coupled to endoplasmic reticulum stress in liver cancer cells. J Pharmacol Exp Ther 2009;329:808-819.
24. Kwon GT, Cho HJ, Chung WY, Park KK, Moon A, Park JH: Isoliquiritigenin inhibits migration and invasion of prostate cancer cells: Possible mediation by decreased JNK/AP-1 signaling. J Nutr Biochem 2009;20:663-676.
25. Cho HJ, Kim WK, Kim EJ, Jung KC, Park S, Lee HS, Tyner AL, Park JH: Conjugated linoleic acid inhibits cell proliferation and ErbB3 signaling in HT-29 human colon cell line. Am J Physiol 2003;284:G996-G1005. (Pubitemid 36597343)
26. Di Lorenzo G, Tortora G, D'Armiento FP, De Rosa G, Staibano S, Autorino R, D'Armiento M, De Laurentiis M, De Placido S, Catalano G, Bianco AR, Ciardiello F: Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer. Clin Cancer Res 2002;8:3438-3444. (Pubitemid 35340719)
27. Wells A, Kassis J, Solava J, Turner T, Lauffenburger DA: Growth factor-induced cell motility in tumor invasion. Acta Oncol 2002;41:124-130. (Pubitemid 34557071)
28. Gullett NP, Ruhul Amin AR, Bayraktar S, Pezzuto JM, Shin DM, Khuri FR, Aggarwal BB, Surh YJ, Kucuk O: Cancer prevention with natural compounds. Semin Oncol 2010;37:258-281.
29. Lu X, Kang Y: Epidermal growth factor signalling and bone metastasis. Br J Cancer 2010;102:457-461.
30. De Miguel P, Royuela, Bethencourt R, Ruiz A, Fraile B, Paniagua R. Immunohistochemical comparative analysis of transforming growth factor alpha, epidermal growth factor, and epidermal growth factor receptor in normal, hyperplastic and neoplastic human prostates. Cytokine 1999;11:722-727. (Pubitemid 29428006)
31. Ding Y, Brackenbury WJ, Onganer PU, Montano X, Porter LM, Bates LF, Djamgoz MB: Epidermal growth factor upregulates motility of Mat-LyLu rat prostate cancer cells partially via voltage-gated Na+ channel activity. J Cell Physiol 2008;215: 77-81. (Pubitemid 351363193)
32. Uysal-Onganer P, Djamgoz MB: Epidermal growth factor potentiates in vitro metastatic behaviour of human prostate cancer PC-3M cells: Involvement of voltage-gated sodium channel. Mol Cancer 2007;6:76.
33. Kleiner DE, Stetler-Stevenson WG: Matrix metalloproteinases and metastasis. Cancer Chemother Pharmacol 1999;43(Suppl): S42-S51. (Pubitemid 29244632)
34. Hidalgo M, Eckhardt SG: Development of matrix metalloproteinase inhibitors in cancer therapy. J Natl Cancer Inst 2001; 93:178-193. (Pubitemid 32166488)
35. Ramnath N, Creaven PJ: Matrix metalloproteinase inhibitors. Current Oncol Rep 2004;6:96-102. (Pubitemid 38898836)
36. Pavlaki M, Zucker S. Matrix metalloproteinase inhibitors (MMPIs): The beginning of phase I or the termination of phase III clinical trials. Cancer Metastasis Rev 2003;22:177-203. (Pubitemid 36561057)
37. Soula-Rothhut M, Coissard C, Sartelet H, Boudot C, Bellon G, Martiny L, Rothhut B: The tumor suppressor PTEN inhibits EGF-induced TSP-1 and TIMP-1 expression in FTC-133 thyroid carcinoma cells. Exp Cell Res 2005;304:187-201. (Pubitemid 40222087)
38. Chirco R, Liu XW, Jung KK, Kim HR: Novel functions of TIMPs in cell signaling. Cancer Metastasis Rev 2006;25:99-113. (Pubitemid 43723986)
39. Gomez DE, Alonso DF, Yoshiji H, Thorgeirsson UP: Tissue inhibitors of metalloproteinases: Structure, regulation and biological functions. Eur J Cell Biol 1997;74:111-122. (Pubitemid 27455388)
40. Kim EJ, Shin M, Park H, Hong JE, Shin HK, Kim J, Kwon DY, Park JH: Oral administration of 3,3'-diindolylmethane inhibits lung metastasis of 4T1 murine mammary carcinoma cells in BALB/c mice. J Nutr 2009;139:2373-2379.
41. Joo YE, Seo YH, Lee WS, Kim HS, Choi SK, Rew JS, Park CS, Kim SJ: Expression of tissue inhibitors of metalloproteinases (TIMPs) in hepatocellular carcinoma. Korean J Intern Med 2000; 15:171-178.
42. Kuvaja P, Talvensaari-Mattila A, Turpeenniemi-Hujanen T. High preoperative plasma TIMP-1 is prognostic for early relapse in primary breast carcinoma. Int J Cancer 2008;123:846-851. (Pubitemid 352032411)